drugset / Trial / NCT06234904
Study of IBR733 Cell Injection in Acute Myeloid Leukemia
Phase 1
Recruiting
18 enrolled
Imbioray (Hangzhou) Biomedicine Co., Ltd.
The First Affiliated Hospital of Soochow University · collab
NaSequentialOpen-labelTreatment
Summary
This is an open-label clinical study: phase Ia is the dose-escalation part, and phase Ib is the dose-expansion part. The phase Ia study is to evaluate the safety, tolerability, recommended phase II dose, pharmacokinetics, immunogenicity and preliminary efficacy of IBR733 cell injection in relapsed/refractory acute myeloid leukemia (AML).
Timeline
- Start
- 2024-03-26
- Primary completion
- 2027-07-01
- Completion
- 2027-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBR733 | Cell therapy | 5e+09 cells | Intravenous |
| Subject | IBR733 | Cell therapy | 7.5e+09 cells | Intravenous |
| Subject | IBR733 | Cell therapy | 1e+10 cells | Intravenous |